ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease
ExonHit is a fast emerging healthcare player developing innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. The Company is listed on Alternext of NYSE Euronext Paris.
Navigation
2010
-
February 11, 2010 -
February 23, 2010
ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration
-
March 3, 2010
ExonHit reports out-licensing of EHT/AGN 0001 by Allergan to Bristol-Myers Squibb
-
March 8, 2010
ExonHit and bioMérieux decide not to pursue colon cancer program
-
March 10, 2010
ExonHit Therapeutics reports 2009 annual results
2009
-
December 16, 2009
ExonHit announces the success of its capital increase
-
December 3, 2009
ExonHit launches first product in Alzheimer
-
November 5, 2009
ExonHit Therapeutics announces the appointment of its new Chief Financial Officer
-
November 2, 2009
ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people
-
October 30, 2009
ExonHit presents new clinical advances on its Alzheimer’s diagnostic and therapeutic programs
-
October 26, 2009
ExonHit strengthens its intellectual property position in the US
-
September 14, 2009
ExonHit presents promising first patient results for EHT 0202, its Alzheimer’s candidate drug
-
September 8, 2009
ExonHit will participate to the Paris Midcap Event on September 21 & 22
-
July 30, 2009
ExonHit Therapeutics – First half 2009 results
-
July 8, 2009
ExonHit raises EUR 1.45 million through the exercise of warrants
-
June 26, 2009
ExonHit announces the departure of its Chief Financial Officer
-
June 16, 2009
ExonHit announces last patient out for EHT 0202 Phase IIa study in Alzheimer
-
May 27, 2009
ExonHit and Institut Gustave Roussy announce the signing of a license agreement for novel breast cancer diagnostic assay.
-
May 19, 2009
ExonHit enters into a liquidity agreement.
-
May 6, 2009
ExonHit’s 2009 Extraordinary Annual Meeting.
-
April 28, 2009
ExonHit’s 2009 Ordinary Annual Meeting.
-
April 16, 2009
ExonHit will participate to the paris Smallcap event.
-
March 31, 2009
ExonHit expands neurological research activities to epilepsy.
-
March 16, 2009
ExonHit reports proof of concept in breast cancer diagnostic using its SpliceArrayTM platform.
-
March 9, 2009
ExonHit Therapeutics shareholders equity strengthened by exercice of more than half of its convertible bonds.
-
March 4, 2009
ExonHit Terapeutics invested strongly in 2008 for pivotal 2009 results.
-
February 26, 2009
ExonHit Therapeutics reports advancements in the clinical development of EHT 0202, its phase II drug for Alzheimer's disease.
-
January 6,2009
ExonHit therapeutics expands strategic collaboration with allergan.
2008
-
December 23,2008
ExonHit Therapeutics allocates free subscription warrants to all shareholders.
-
December 3,2008
ExonHit is honoured by the innovation trophy from the nationnal institute of industrial property.
-
November 27,2008
ExonHit launches mouse genome SpliceArrayTM for use in human disease modeling studies.
-
October 29,2008
ExonHit announces new scientific publications on the use of SpliceArrayT.
-
September 22,2008
ExonHit exclusive partnership with Xentech to provide molecular profiling services.
-
July 29,2008
ExonHit Therapeutics achievements for first half.
-
July 2,2008
ExonHit presents therapeutic and diagnostic programs for Alzheimer at ICAD.
-
June 4,2008
Loic Maurel joins ExonHit therapeutics to become CEO.
-
May 6,2008
ExonHit therapeutics launches the rat genome SpliceArrayT products.
-
April 30, 2008
Appointment of Frederic Desdouits on the supervisory board of ExonHit Therapeutics.
-
March 31,2008
ExonHit appoints a new Management Board.
-
March 25,2008
Exonhits EHT 0202 counters scopolamines detrimental.
-
March 5,2008
ExonHit therapeutics financial results 2007.
-
January 16,2008
ExonHit builds a new organization.
-
January 9,2008
ExonHit and bioMerieux amend their strategic partnership.
2007
-
January 4, 2007
ExonHit Therapeutics and bioMerieux initiate a third diagnostic programme
-
January 25, 2007
ExonHit raises 3.2 million euros through the exercise of warrants
-
February 20, 2007
ExonHit launches Human Genome SpliceArrayTM
-
February 26, 2007
ExonHit issues 400 000 new shares through the use of PACEO
-
March 6, 2007
ExonHit 2006 financial results
-
March 15, 2007
ExonHit identifies a panel of genes to diagnose, from a blood, Alzheimer's disease
-
April 17, 2007
ExonHit Therapeutics and bioMérieux present additional results in their breast cancer blood biomarkers program
-
May 11, 2007
Deborah Smeltzer appointed member of the supervisory board of ExonHit Therapeutics
-
June 1st, 2007
ExonHit issues 400 000 new shares through the use of PACEO
-
June 7, 2007
In 2009 ExonHit aims to ask for market clearance in Europe for a blood diagnostic test for Alzheimer's disease
-
July 31, 2007
ExonHit Therapeutics - Achievements for first half 2007
-
August 28, 2007
ExonHit strikes a milestone in its collaboration with Allergan
-
November 8, 2007
ExonHit completes a prototype to detect Alzheimer's disease from blood
-
December 20, 2007
ExonHit initiates a Phase 2 clinical trial for EHT 0202 in Alzheimer's disease
2006
-
November 23, 2006
ExonHit Therapeutics - Clinical Therapeutic Programs
-
November 8, 2006
Appointment of a new member of the Supervisory Board
-
October 25, 2006
ExonHit success of the issuance of convertible bonds
-
October 24, 2006
ExonHit presents preliminary characteristics of the issuance of convertible bonds
-
October 19, 2006
ExonHit to start a research program on a blood diagnostic for Atherosclerosis
-
September 20, 2006
ExonHit Therapeutics - solid first half 2006
-
September 19, 2006
ExonHit extends strategic alliance with Allergan
-
September 12, 2006
ExonHit appoints John Jaskowiak as Executive Business and marketing
-
September 12, 2006
ExonHit - internet portal to market its microarrays
-
September 7, 2006
ExonHit licences Merck rights to RNA splicing microarray patent
-
September, 7 2006
ExonHit produces a new map for human genome expression
-
July 25, 2006
First half 2006 revenues up by 46%
-
july 5, 2006
ExonHit - Financial press release calendar
-
June 7, 2006
ExonHit - Emission of free warrants
-
June 16, 2006
ExonHit - Success of the secondary offering
-
June 14, 2006
Changes in the secondary offering
-
June 7, 2006
ExonHit - Secondary offering and free allocation of BSA
-
May 31, 2006
Agilent and ExonHit expand agreement
-
May 16, 2006
Alzheimer disease diagnostic patent
-
April 18, 2006
SpliceArrays on Affymetrix GeneChip platform
-
April 5, 2006
ExonHit annonces the partial release of the lock-up for its principal shareholders
-
March 29, 2006
ExonHit bioMérieux breast cancer
-
February 21, 2006
2005 Financial Results
-
February 17, 2006
ExonHit therapeutics will begin continuous trading on Alternext on March 6, 2006
-
February 9, 2006
ExonHit’ SpliceArray service welcomes its 50th commercial project
-
January 5, 2006
ExonHit therapeutics strengthens its balance sheet